4/A: Vericel Corp Executive Sean Flynn Corrects Form 4 Filing to Indicate 10b5-1 Trading Plan

Sean Flynn, SVP and General Counsel of Vericel Corp, files an amended Form 4 to properly indicate a sale of 8,115 shares was executed under a pre-arranged 10b5-1 trading plan.

Summary

• Sean Flynn, SVP and General Counsel of Vericel Corp, filed an amended Form 4 (Form 4/A) with the SEC.
• The amendment corrects an oversight in the original Form 4 filed on March 11, 2024.
• The original filing inadvertently omitted the indication that a transaction was made pursuant to a Rule 10b5-1(c) trading plan.
• The corrected filing confirms the sale of 8,115 shares of Vericel Corp common stock on March 8, 2024, was executed under this plan.
• The sale price was $45.33 per share.
• Following the transaction, Flynn directly owns 167 shares of Vericel Corp.
• The 10b5-1 trading plan was adopted on November 15, 2023.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The correction to indicate a 10b5-1 plan is important for regulatory compliance and investor understanding, as it suggests the sale was pre-planned and not based on recent inside information.

Stakeholder Impact

• The correction provides clarity to shareholders regarding the nature of the transaction.

Key Dates